← Eichor
Study identifier: NCT06709859 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Condition: Carcinoma, Non-Small-Cell Lung  ·  Sponsor: Shandong Public Health Clinical Center

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase II, single-arm study to evaluate the efficacy and safety of Afatinib plus chemotherapy as conversion treatment in patients with unresectable EGFR sensitive mutation-positive stage III non-small cell lung cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Hua Zhang, PhD  ·  0531-83347512  ·  95192789@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shandong Public Health Clinical CenterJinan, Shangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06709859